|
Oct 24
|
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
|
|
Oct 24
|
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
|
|
Oct 24
|
3 Biotech Stocks With Decent Dividend for a Steady Return
|
|
Oct 23
|
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
|
|
Aug 31
|
With 86% institutional ownership, Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst the big guns
|
|
Aug 30
|
Gilead Sciences: Fifth Anniversary of COMPASS: Helping Address the HIV Epidemic in the U.S. South
|
|
Aug 29
|
Nearing Retirement? These Stocks Will Pay You For Life
|
|
Aug 28
|
12 Undervalued Wide Moat Stocks To Invest In
|
|
Aug 27
|
Here's Why We Think Gilead Sciences (NASDAQ:GILD) Is Well Worth Watching
|
|
Jul 20
|
A Note On Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE and Debt To Equity
|
|
Jul 19
|
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
|
|
Jul 19
|
Gilead Sciences: Putting a Spotlight on the Mental Health Needs of LGBTQ+ Youth
|
|
Jul 19
|
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
|
|
Jul 19
|
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
|
|
Jul 17
|
Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion
|
|
Jul 17
|
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
|
|
Jul 14
|
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
|
|
Jul 14
|
FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment
|
|
Jul 14
|
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
|
|
Jul 13
|
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
|